BriaCell Therapeutics

BriaCell has engaged Charles River Associates and Kaleio to develop the commercial strategy and assess market access for the investigational therapy Bria‑IMT in metastatic breast cancer. CRAI will analyze epidemiology, pricing, prescribing dynamics and market access potential in the US, while Kaleio will develop brand strategies and market‑readiness solutions. Bria‑IMT is currently being evaluated in an approval‑relevant phase 3 study (NCT06072612) and does not yet have commercial approval. According to BriaCell, the consulting engagements are an important step in preparing for future commercialization and regulatory processes. » More on de.investing.com

BriaCell Therapeutics released results for the quarter ended 30 April 2026 and reported a loss per share of 1.36 CAD. In the prior-year quarter, -23,320 CAD per share was recorded. No further financial metrics were reported. » More on finanzen.net

BriaCell has finished producing the clinical trial material for Bria-PROS+, a cell-based immunotherapy for prostate cancer, and plans to start a Phase 1/2a study in the coming months. The stock traded near its 52-week high after rising about 20% over the past six months. According to preclinical data, Bria-PROS+ activated adaptive and innate immune responses; the project was supported by a $2 million grant from the U.S. National Cancer Institute. The Bria-PROS+ platform is based on the same technology as Bria-BRES+, for which an IND was recently approved, and the company points to positive results from its Bria-OTS program in breast cancer. » More on de.investing.com